Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 5/20 | 0.52 |
| ▸ | CCR1 | P32246 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 6/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.46 |
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6980908 | 0.85 | CCR3 (0.54) | CCR3CCR1NPC1RAB9AMEN1 | |
| SCHEMBL6980792 | 0.81 | HDAC8 (0.56) | CCR3CCR1NPC1RAB9AMEN1 | |
| SCHEMBL6980795 | 0.81 | HDAC8 (0.56) | CCR3CCR1NPC1RAB9AMEN1 | |
| SCHEMBL7594053 | 0.80 | SLC6A2 (0.46) | DRD2SLC6A4SLC6A2DRD4DRD3 | |
| SCHEMBL6980905 | 0.77 | LTA4H (0.56) | CCR3CCR1NPC1RAB9AMEN1 | |
| SCHEMBL6980910 | 0.77 | LTA4H (0.56) | CCR3CCR1NPC1RAB9AMEN1 | |
| SCHEMBL6979906 | 0.75 | ACHE (0.63) | CCR3CCR1NPC1RAB9ALTA4H | |
| SCHEMBL6981212 | 0.72 | MEN1 (0.49) | CCR3CCR1NPC1RAB9AMEN1 | |
| SCHEMBL6981210 | 0.72 | MEN1 (0.49) | CCR3CCR1NPC1RAB9AMEN1 | |
| SCHEMBL6981216 | 0.72 | MEN1 (0.49) | CCR3CCR1NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0606248-B1 | HETEROARYL AMINES AS NOVEL ACETYL CHOLINESTERASE INHIBITORS | EISAI CO LTD (JP) | 2003-03-26 | — | — | EP | disclosed |
| US-20020049210-A1 | Heteroaryl amines as novel acetylcholinesterase inhibitors | CHEN YUHPYNG L (US) | 2002-04-25 | — | — | US | disclosed |
| US-6303633-B1 | FOR THERAPY AND PROPHYLAXIS OF ALZHEIMER'S DISEASE | PFIZER INC | 2001-10-16 | — | — | US | disclosed |
| US-6124321-A | Heteroaryl amines as novel acetyl cholinesterase inhibitors | PFIZER INC (US) | 2000-09-26 | — | — | US | disclosed |
| US-5965574-A | Heteroaryl amines as novel acetylcholinesterase inhibitors | CHEN YUHPYNG LIANG (US) | 1999-10-12 | — | — | US | disclosed |
| US-5574046-A | Heteroaryl amines as novel acetylcholinesterase inhibitors | PFIZER INC. (US) | 1996-11-12 | — | — | US | disclosed |
| WO-1993007140-A1 | HETEROARYL AMINES AS NOVEL ACETYL CHOLINESTERASE INHIBITORS | PFIZER INC. (US) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049210-A1 | Heteroaryl amines as novel acetylcholinesterase inhibitors | ACHE, BCHE, CHAT | CCR3 4118/4885CCR1 3895/4885NPC1 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.